GC
Jeff Cislini is the Senior Vice President, General Counsel, and Secretary at Revolution Medicines, Inc. (RVMD), a role he has held since September 2022, following his position as Vice President, Deputy General Counsel from June 2020 to September 2022.[[1]](https://fintool.com/app/research/companies/RVMD/people/jeff-cislini)[[3]](https://www.revmed.com/team/jeff-cislini-j-d/)[[4]](https://www.zoominfo.com/p/Jeffrey-Cislini/1255316006) Prior to joining RVMD, he served as Vice President, Legal, Corporate & Contracts, and Corporate Secretary at Atara Biotherapeutics from 2018 to 2020, and worked as an attorney at O’Melveny & Myers LLP (2007–2018) and Wilson Sonsini Goodrich & Rosati, P.C. (2001–2007), specializing in corporate, life sciences, technology, and biotech law.[[1]](https://fintool.com/app/research/companies/RVMD/people/jeff-cislini)
Cislini holds a B.A.S. in Economics and Land Resources Planning from Stanford University and a J.D. from Harvard Law School; he is approximately 50 years old as of March 2025.[[1]](https://fintool.com/app/research/companies/RVMD/people/jeff-cislini) As a corporate insider, he has conducted recent stock sales under a 10b5-1 trading plan, including 1,799 shares on September 24, 2025 ($79,623), 13,388 shares on November 18, 2025, and 2,688 shares on December 18, 2025 ($206,484), retaining 50,425 shares post-September transaction.[[2]](https://www.investing.com/news/insider-trading-news/cislini-jeff-general-counsel-at-revolution-medicines-sells-79623-in-stock-93CH-4258311)[[5]](https://www.tradingview.com/news/tradingview:734c94624cdd8:0-executives-at-revolution-medicines-conduct-stock-transactions/)[[7]](https://www.secform4.com/insider-trading/1969082.htm)
View full insider profile →
